Nephrolithiasis Clinical Trial
— DESYOfficial title:
Pharmacodynamic Evaluation of the ANTICALCIURIC Effect of Hydrochlorothiazide in Dent's Disease
Verified date | July 2003 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
Intrarenal calcifications (nephrocalcinosis) is present in Dent's disease and likely contribute to progression toward renal failure. In order to prevent this complication it is usually proposed to treat affected patients during childhood with high doses of thiazides.
Status | Terminated |
Enrollment | 10 |
Est. completion date | December 2005 |
Est. primary completion date | December 2005 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 3 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Children > 3 yrs old who met at least three standard criteria for Dent's disease including hypercalciuria, low molecular weight proteinuria and one of the following disorders: nephrocalcinosis, nephrolithiasis, renal failure, aminoaciduria, glucosuria, renal phosphate wasting, or familial history of Dent's disease. - Dent's Disease confirmed by direct sequencing of the CLCN5 gene according to Lloyd et al. Exclusion Criteria: - Patients presenting hyponatremia (< 135 mM), hypokalaemia (< 3.3 mM), severe fanconi syndrome, or chronic renal failure (GFR estimated with the Schwartz formula < 30 mL.min-1.1.73m-2) were excluded from the study. - Overt renal loss of sodium - Inability to adapt to severe sodium restriction |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Centre d'investigation clinique HOPITAL GEORGE POMPIDOU | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | to investigate the dose-dependent benefit/risk ratio of low (6.25 mg/day), intermediate (12.5 mg/day) and high (25 mg/day) doses of hydrochlorothiazide | at the end of the baseline initial and final washout periods (one month each) and at the end of each two-months duration treatment period, | Yes | |
Secondary | clinical events (cramps, symptomatic dehydration, acute weight loss) | at least two times overall the study, at J15 and at the end of each period. | Yes | |
Secondary | Biological : acute renal failure (estimated GFR), hypokalemia, hyperkalemia, hyponatremia, biological signs of extra cellular dehydration (protides, hematocrit, plasma active renin, plasma aldosterone) | at least two times overall the study, at J15 and at the end of each period. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04746378 -
PRedictive Accuracy of Initial Stone Burden Evaluation.
|
||
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT03692715 -
Antibiotic Prophylaxis Before Shock Wave Lithotripsy
|
Phase 4 | |
Completed |
NCT02547805 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
|
Phase 2 | |
Completed |
NCT02289755 -
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
|
Phase 2 | |
Completed |
NCT01650935 -
Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria
|
N/A | |
Completed |
NCT01690039 -
Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
|
||
Completed |
NCT01295879 -
Vitamin D Repletion in Stone Formers With Hypercalciuria
|
Phase 4 | |
Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
Not yet recruiting |
NCT06199102 -
The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants.
|
N/A | |
Recruiting |
NCT04367155 -
Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.
|
N/A | |
Recruiting |
NCT04374188 -
Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy
|
N/A | |
Recruiting |
NCT05701098 -
SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)
|
N/A | |
Recruiting |
NCT04389853 -
Mini-PNCL vs fURS in Management of Nephrolithiasis
|
N/A | |
Completed |
NCT03348228 -
Effect of Hydroxycitrate on Urine Chemistry
|
N/A | |
Completed |
NCT05350423 -
Trial Assessing Renal Damage During Ureteroscopy
|
N/A | |
Completed |
NCT03454139 -
Subcostal TAP Block For Percutaneous Nephrolithotomy
|
N/A | |
Recruiting |
NCT02279927 -
Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy
|
N/A | |
Completed |
NCT02276924 -
Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors
|
N/A | |
Completed |
NCT00159393 -
Percutaneous Nephrolithotomy: A Registry and Database
|